Back to top

Image: Bigstock

Why Earnings Season Could Be Great for MEDNAX (MD)

Read MoreHide Full Article

Investors are always looking for stocks that are poised to beat at earnings season and MEDNAX, Inc. (MD - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because MEDNAX is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for MD in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at 93 cents per share for MD, compared to a broader Zacks Consensus Estimate of 91 cents per share. This suggests that analysts have very recently bumped up their estimates for MD, giving the stock a Zacks Earnings ESP of +2.20% heading into earnings season.

Mednax, Inc Price and EPS Surprise

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that MD has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for MEDNAX, and that a beat might be in the cards for the upcoming report.

Free: Zacks’ Single Best Stock Set to Double

Today you are invited to download our just-released Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.

Download Free Report Now >>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Mednax, Inc (MD) - free report >>